

1 **Name of Journal:** *World Journal of Gastroenterology*

2 **Manuscript Type:** BASIC STUDY

3 **Relationship between Pancreatic Cancer Autophagy and Perineural**
4 **Invasion, Clinicopathological Features and Prognosis**

5 Yang YH et al. Pancreatic Cancer Autophagy and Perineural Invasion

6 **Yan-Hui Yang, Jiang-Bo Liu, Yang Gui, Liang-Liang Lei, Shui-Jun Zhang**

7 **Yan-Hui Yang, Shui-Jun Zhang**, Department of Hepatobiliary and Pancreatic
8 Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou
9 450052, Henan Province, China.

10 **Jiang-Bo Liu, Liang-Liang Lei**, Department of General Surgery, First
11 Affiliated Hospital, College of Clinical Medicine, Henan University of Science
12 and Technology, Luoyang 471000, Henan Province, China.

13 **Yan-Hui Yang, Yang Gui**, Department of Hepatobiliary Surgery, First
14 Affiliated Hospital, College of Clinical Medicine, Henan University of Science
15 and Technology, Luoyang 471000, Henan Province, China.

16 **Author contributions:** Yang YH and Liu JB contributed equally to this work;
17 Yang YH and Liu JB performed the majority of the experiments; Gui Y and
18 Lei LL assisted with various experiments and helped to analyze the data;
19 Zhang SJ and Liu JB drafted and edited the manuscript; Yang YH, Liu JB
20 performed critical revision of the manuscript.

21 **Supported by** the National Natural Science Foundation of China, No.
22 U1504815.

23 **Institutional review board statement:** The study was reviewed and approved
24 by the Institutional Review Board of First Affiliated Hospital of Zhengzhou
25 University.

1 **Conflict-of-interest statement:** The authors declare no competing interests.

2 **Data sharing statement:** No additional unpublished data are available.

3 **Address correspondence to:** Shui-Jun Zhang, MD, PhD, Department of
4 Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of
5 Zhengzhou University, Zhengzhou 450052, Henan Province, China.
6 zhangshuijun@zzu.edu.cn.

7 Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated
8 Hospital of Zhengzhou University, Zhengzhou, Henan, China.

9 Henan Key Laboratory of Digestive Organ Transplantation.

10 Open and Key Laboratory of Hepatobiliary & Pancreatic Surgery and
11 Digestive Organ Transplantation at Henan Universities.

12 Zhengzhou Key Laboratory of Hepatobiliary & Pancreatic Diseases and
13 Organ Transplantation.

14 Telephone: +86-0371-66964992

15 Fax: +86-0371-66964992

16

1 **Abstract**

2 **AIM:** To investigate the relationship between autophagy and perineural
3 invasion (PNI) , clinical features and prognosis in patients with pancreatic
4 cancer.

5 **METHODS:** Clinical and pathological data were retrospectively collected
6 from 109 patients with pancreatic ductal adenocarcinoma who underwent
7 resection at the First Affiliated Hospital of Zhengzhou University from
8 January 2011 to August 2016. Expression levels of the autophagy-related
9 protein microtubule-associated protein 1A/1B-light chain 3 (LC3) and
10 perineural invasion marker ubiquitin carboxy-terminal hydrolase (UCH) in
11 pancreatic cancer tissues were detected by immunohistochemistry. The
12 correlations among LC3 expression, perineural invasion, and clinical
13 pathological features in pancreatic cancer were analyzed. The patients were
14 followed up for further survival analysis.

15 **RESULTS:** In 109 cases of pancreatic cancer, 68.8% (75/109) had evidence of
16 perineural invasion and 61.5% (67/109) had high LC3 expression. Perineural
17 invasion was associated with lymph node metastasis, pancreatitis and CA19-9
18 levels ($P<0.05$). LC3 expression was related to lymph node metastasis ($P<0.05$)
19 and was positively correlated with neural invasion ($P<0.05$, $r=0.227$).
20 Multivariate logistic regression analysis indicated that LC3, lymph node
21 metastasis, pancreatitis, and CA19-9 level were factors that influenced neural
22 invasion, whereas only neural invasion itself was an independent factor of
23 high LC3 expression. Univariate analysis showed that LC3 expression, neural
24 invasion and CA19-9 level were related to the overall survival of pancreatic
25 cancer patients ($P<0.05$). Multivariate COX regression analysis indicated that
26 perineural invasion and LC3 expression were independent risk factors for
27 poor prognosis in pancreatic cancer ($P<0.05$).

1 **CONCLUSION:** Perineural invasion in patients with pancreatic cancer is
2 positively related to autophagy. Neural invasion and LC3 expression are
3 independent risk factors for pancreatic cancer with poor prognosis.

4 **Key words:** Pancreatic cancer; Perineural invasion; Autophagy; Clinical
5 pathological features; Prognosis

6 **Core tip:** The relationship between autophagy and perineural invasion (PNI)
7 was explored for the first time in pancreatic cancer. Pancreatic cancer PNI is
8 related to LC3 expression-determined autophagy. PNI and LC3 expression
9 were independent prognostic factors in pancreatic cancer. There might be a
10 special association between autophagy and PNI, contributing to pancreatic
11 cancer progression. This study might provide a new insight for the
12 mechanism of PNI in pancreatic cancer.

13 **Yang YH, Liu JB, Gui Y, Lei LL and Zhang SJ.** Relationship between
14 Pancreatic Cancer Autophagy and Perineural Invasion, Clinicopathological
15 Features and Prognosis

16

1 Introduction

2 Pancreatic cancer, also known as “the king of cancer”, is a malignant tumor
3 with a poor prognosis that has almost equal mortality and morbidity in
4 patients. The incidence of pancreatic cancer is increasing yearly^[1]. Surgical
5 resection is the only possible cure of pancreatic cancer, although less than 20%
6 of patients are eligible for radical surgery^[2]. At the time of diagnosis, most
7 pancreatic cancer patients have distant metastases due to early occult
8 symptoms, a lack of effective screening, and perineural growth characteristics.

9 The incidence of perineural invasion (PNI) in pancreatic cancer is up to 80-100%
10 and is an important factor leading to postoperative pancreatic cancer
11 recurrence. Previous studies have shown a higher recurrence rate after
12 surgery and shorter disease-free and overall survival rates in cases of
13 pancreatic cancer with PNI compared with those of cases without PNI. PNI
14 evaluation of pancreatic cancer can predict disease recurrence and prognosis
15 after surgery^[3, 4]. However, the pathogenesis of PNI has not yet been defined.

16 Autophagy has a dual role in promoting and inhibiting tumor growth^{[5,}
17 ^{6]}. Autophagy, as a mechanism of anoikis avoidance in pancreatic cancer, is
18 closely related to the survival of pancreatic cancer cells. Microtubule-
19 associated protein 1A/1B-light chain 3 (LC3) is a typical marker of autophagy.
20 LC3 labeling has been used to evaluate autophagy, and high levels of LC3
21 expression have been found in pancreatic cancer cells^[7]. In addition, previous
22 study also showed that pancreatic cancer cells with PNI have higher levels of
23 autophagy^[7].

24 No study has examined the relationship between autophagy and PNI in
25 pancreatic cancer cells. However, it can be inferred that only those pancreatic
26 cancer cells that can survive within nerve tissues can eventually develop into
27 a clinically visible form of pancreatic cancer PNI. Autophagy is likely one of
28 the mechanisms involved in cancer cell survival. Therefore, this study focused
29 on the relationship between pancreatic cancer cell autophagy and PNI,
30 clinicopathological features and prognosis and provides a clinical basis for

1 further study of the autophagy mechanisms affecting the pathogenesis of
2 pancreatic cancer PNI.

3

4 **Materials and Methods**

5 **General data**

6 Retrospective data were collected from 109 cases of pathology-confirmed
7 pancreatic ductal adenocarcinoma patients who underwent radical surgery
8 for pancreatic cancer from January 2011 to August 2016 at the First Affiliated
9 Hospital of Zhengzhou University. The included pancreatic cancer patients
10 were not treated with radiation or chemotherapy prior to surgery, but
11 received post-operatively adjuvant gemcitabine- or non-gemcitabine-based
12 chemotherapy, and/or radiotherapy. Tissue specimens were fixed in formalin
13 and paraffin embedded for histological study. Clinical and pathological data
14 were collected, and all cases were followed up. The date of surgical resection
15 was considered as the starting time, and August 2016 was the deadline. The
16 primary end-point was death due to pancreatic cancer. Eighty cases were
17 followed up for more than 12 months. All patients provided informed consent
18 for the collection of biological samples, and this study was approved by the
19 Institutional Review Board of First Affiliated Hospital of Zhengzhou
20 University (Scientific Research No. 5, 2015).

21 Out of the 109 patients studied, 61 cases were male, and 48 cases were
22 female. Their ages ranged from 19 to 81 years, and the median age was 59
23 years. Tumor diameters ranged from 0.7–12 cm with a median value of 4.0 cm.
24 The survival time of 80 patients who were followed up for more than 12
25 months was 1 to 54 months, and the median survival time was 20 months. By
26 the end of the follow-up period, 38 patients had died. The clinical stages were

1 classified according to the AJCC 2011 standard.

2

3 **Immunohistochemistry**

4 Expression levels of LC3 and the nerve fiber marker ubiquitin carboxy-
5 terminal hydrolase (UCH) were detected by immunohistochemistry using a
6 standardized streptavidin-peroxidase (SP) method and the SP
7 immunohistochemical Kit (ZSGB-Bio, Beijing, China) according to the
8 manufacturer's instructions. The pancreatic cancer tissues were routinely
9 embedded in paraffin and sliced into 4- μ m-thick continuous sections. The
10 sections were then warmed in an autoclave to remove residual wax and were
11 hydrated before antigen retrieval. Endogenous peroxidase activity was
12 eliminated by incubating the tissue sections at room temperature with 3%
13 H₂O₂ for 10 min. The tissue sections were washed 3 times with PBS
14 continuously and incubated with a small amount of goat serum at room
15 temperature in a closed chamber for 15 min. The goat serum was then poured
16 off the slides (not washed), and anti-LC3 (Proteintech Group, diluted 1:120)
17 and-UCH antibodies (Proteintech, diluted 1:100) were added, and the slides
18 were incubated overnight at 4°C. The next day, the slides were thoroughly
19 washed with PBS, a biotinylated secondary antibody in a working liquid was
20 added, and the slides were incubated at room temperature for 15 min. After
21 the slides were washed carefully with PBS again, horseradish peroxidase was
22 added, and the slides were incubated for 5 min at room temperature. The
23 slides were then rinsed with PBS three times, and a drop of DAB buffer was
24 placed on the tissue slice and rinsed after 1 min to stop the color reaction.
25 Then, the nucleus was then stained with hematoxylin, and the samples were
26 placed in gradient alcohol, dehydrated with formaldehyde, covered with
27 transparent balata, and observed by microscopy. PBS was used in place of the
28 first antibody to serve as a negative reference sample, and a known positive
29 slice served as the positive control. The immunohistochemical results were
30 evaluated in a double-blind manner by two pathologists. If the results were

1 inconsistent, a third pathologist reviewed the data, and a consensus was
2 reached.

3

4 **LC3 immunohistochemical score**

5 LC3-positive cells by immunohistochemistry required the following
6 characteristics: (1) clear cell structure; (2) accurate localization of the positive
7 particle; and (3) obviously higher pigmentation than that of the background
8 and clear contrast. Positive LC3 expression was mainly localized in pancreatic
9 cancer cell cytoplasm. Five random power fields (400X magnification) were
10 observed for each case using an optical microscope. One hundred
11 homogeneous cells were counted, and the staining intensities and the
12 proportion of positive cells were observed. A semi-quantitative analysis was
13 conducted using the product method. (1) Dye intensity was scored as follows:
14 no yellow, 0 points; light yellow, 1 point; yellow or deep yellow, 2 points; and
15 brown or tan, 3 points. (2) The expression range was scored as follows: <10%,
16 0 points; 10 to 25%, 1 point; 26 to 50%, 2 points; 51 to 75%, 3 points; and >75%,
17 4 points. The value from step (1) was then multiplied by the value from step
18 (2): 0 points, negative (-); 1 to 3 points, weakly positive (+); 4 to 6 points,
19 moderately positive (+ +); and 7 to 12 points, strongly positive (+ + +). More
20 than 3 points indicated high expression, and 3 points or fewer indicated low
21 expression.

22

23 **PNI judging**

24 UCH was expressed in the cytoplasm of all nerve fibers. The location of nerve
25 fibers can be clearly defined by UCH, and then determined the invasion of
26 cancer cells to the nerve tissue. According to previous reports, a positive PNI
27 status was determined as cancer cells being found in the perineural spaces,
28 perineurium or nerve tract^[8].

29

30 **Survival analysis**

1 The effects of clinicopathological factors such as LC3 expression and
2 perineural invasion on the overall survival rate in pancreatic cancer were
3 analyzed in 80 patients with more than 12 months of follow-up data. The
4 following factors were included in the survival analysis: LC3 expression, age,
5 gender, tumor location, tumor size, histological grade, clinical stage, vascular
6 invasion, lymph node metastasis, pancreatitis, diabetes status and
7 preoperative CA19-9 level.

8

9 **Data analysis**

10 Statistical analyses were performed using SPSS19.0 and GraphPad Prism 5.0
11 statistical software. Enumeration data were checked by the Chi-square test or
12 the four-grid table Fisher exact probability method. Correlations between
13 clinicopathological factors such as LC3 expression and PNI were analyzed
14 using the Spearman correlation method. LC3 expression and the factors that
15 independently influenced neural infiltration were analyzed using two
16 categories and unconditional logistic regression. Univariate and multivariate
17 analyses were performed on factors that might affect the prognosis according
18 to a COX risk regression model. The survival curve was plotted according to
19 the Kaplan-Meier method. Results were considered significant when $P < 0.05$.

20

21 **Results**

22 **Evaluation of LC3 expression and perineural invasion in pancreatic cancer**

23 LC3 expression was mainly localized to the cytoplasm. In contrast to normal
24 paraneoplastic pancreatic tissues (Fig 1A), the expression of LC3 in pancreatic
25 cancer tissues ranged from low to high in four grades: negative, weak positive,
26 moderately positive and severe positive(Fig 1B-E). The immunohistochemical
27 results indicated that LC3 protein expression was observed in pancreatic
28 ducts, acinar epithelial cells, islet cells and pancreatic cancer tissues. There
29 was significantly increased LC3 protein expression in pancreatic cancer

1 tissues and peritumoral tissues. In 109 pancreatic cancer tissues, forty-two
2 cases had low LC3 expression (termed “low autophagy level”), including 6
3 (5.5%) negative cases and 36 (33%) weakly positive cases (Fig 1B and 1C);
4 while 67 cases had high LC3 expression (termed “high autophagy level”),
5 including 50 (45.9%) that were moderately positive and 17(15.6%) that were
6 strongly positive (Fig 1D and 1E). PNI by pancreatic cancer cells occurred
7 mainly in the pancreatic cancer stroma. According to previous studies^[9], 4
8 types of relationships exist between PNI and cancer nests: no perineural
9 invasion, perineurium invasion, perineural space invasion, and invasion to
10 the nerve fiber tracts. In 109 cases of pancreatic cancer, 75 cases were
11 positive(Fig 1F -I), and 34 cases were negative for nerve invasion. The positive
12 rate of nerve invasion was 68.8%. High LC3 expression was also found in the
13 nests surrounding the PNI (Fig 1I).

14

15 **Relationship between LC3 expression and perineural invasion in pancreatic** 16 **cancer**

17 The analysis of LC3 expression and PNI of pancreatic cancer demonstrated a
18 significant positive correlation between these two parameters ($P=0.018$,
19 correlation coefficient $r=0.227$). LC3 expression in pancreatic cancer tissues
20 with PNI was significantly higher than that in pancreatic cancer tissues
21 without PNI (Table 1).

22

23 **Relationship between pancreatic cancer cell autophagy and perineural** 24 **invasion and clinicopathological features**

25 LC3 expression was associated with lymph node metastasis ($P<0.05$). LC3
26 expression was not related to sex, gender, tumor location, tumor size,
27 histological grade, clinical stage, vascular invasion, or diabetes mellitus status.
28 PNI was related to lymph node metastasis, pancreatitis and CA19-9 levels
29 ($P<0.05$) and was not related to sex, age, tumor location, tumor size,
30 histological grade, clinical stage, vascular invasion, or diabetes mellitus status
31 (Table 2).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Logistic regression multivariate analysis of LC3 expression and perineural invasion

The clinical pathological factors possibly associated with LC3 expression and PNI were evaluated by multivariate analysis using a logistic regression model. The clinical pathological factors included LC3 expression and nerve infiltration, age, tumor site, tumor size, histological grade, clinical stage, vascular invasion, lymph node metastasis, diabetes, pancreatitis, and preoperative CA19-9 level. The results showed that LC3 expression, lymph node metastasis, pancreatitis and CA19-9 level were the factors that influenced the occurrence of PNI, which was an independent factor affecting LC3 expression (Tables 3 and 4).

Survival analysis

According to LC3 expression, patients were divided into high-expression or low-expression groups. The overall survival rate of the low-expression group was better than that of the high-expression group, and the risk of death was 2.78-times higher in the LC3 high-expression group than that in the low-expression group. This difference between the two groups was significant (Fig. 2A). The patients were also divided into a nerve-invasion group and a no-nerve-invasion group according to whether there was nerve infiltration. The overall survival rate of the patients without nerve invasion was better than that of the nerve-invasion group. **The risk of death was 2.93-times greater in the PNI-positive group than that in the PNI-negative group,** and the difference between the two groups was significant (Fig. 2B). Univariate analysis showed that the CA19-9 level, PNI and **LC3 expression** influenced the prognosis (Table 5). A factor of $P<0.2$ was added into the COX risk regression model. Multivariate analysis was performed using the stepwise conditional method. The results showed that PNI and LC3 **expression** were independent prognostic factors that influenced pancreatic cancer (Table 6).

1 **Discussions**

2 Pancreatic cancer has a poor treatment outcome because of a low resection
3 rate, early invasion and metastasis, and insensitivity to radiotherapy and
4 chemotherapy^[10-13]. PNI is common in pancreatic cancer, and also found in
5 breast, prostate and rectal cancers^[14]. A lot of studies have suggested that PNI
6 is the main cause of abdominal pain in patients and is also one of the
7 important causes of local recurrence of pancreatic cancer^[15-19]. PNI is a
8 continuous process involved with multiple molecular factors and tumor
9 microenvironment, but it is unclarified how cancer cells maintain their
10 survival and proliferation from pancreatic cancer tissues to the external
11 pancreatic plexus^[20]. Autophagy is the process of degrading cytoplasmic
12 proteins or organelles through lysosomes. Under physiological conditions,
13 autophagy plays a major role in maintaining the intracellular environment
14 stability^[21, 22]. Autophagy is an important mechanism of escaping apoptosis
15 for tumor cells. Moreover, autophagy may mediate resistance to
16 chemotherapy in pancreatic cancer^[23-25]. Therefore, this study was designed
17 and completed in a retrospective manner to evaluate the relationship between
18 pancreatic cancer autophagy and PNI and patient survival.

19 This study found that high expression of LC3 was present in the cancer
20 nests around the nerve infiltration, consistent with the discovery of Yang^[7]. In
21 histology terms, it has been suggested that high LC3 expression is related to
22 PNI. Further analysis of immunohistochemistry showed that there was a
23 significant positive correlation between LC3 expression and PNI in pancreatic
24 cancer tissues. Therefore, we speculated that, in the PNI process, a high
25 autophagy level may assist cancer cells in escaping apoptosis, avoiding the
26 damage of adverse stress and providing energy for the invasion and

1 metastasis of pancreatic cancer.

2 There is dissidence in the correlation between PNI and lymph node
3 metastasis^[26-28]. This study showed that PNI was associated with lymph node
4 metastasis, pancreatitis, and CA19-9 levels ($P<0.05$), while it had no
5 association with sex, age, tumor location, tumor size, histological grade,
6 clinical stage, vascular invasion or diabetes mellitus. LC3 was related to
7 lymph node metastasis but no other clinicopathological features. Multivariate
8 analysis of logistic regression also showed that LC3, lymph node metastasis,
9 pancreatitis and CA19-9 levels were the factors that influenced PNI, while
10 PNI was an independent factor affecting LC3 expression. Tanaka, A^[26],
11 Duraker N^[28], etc., believe that lymph node metastasis can promote PNI. The
12 cancer cells in lymph node metastases can form a lymphatic satellite around
13 the nerve and then break through the nerve membrane; then, nerve invasion
14 occurs. This study is consistent with results suggesting the need for regional
15 lymph node dissection during surgical treatment^[27]. Through this study, we
16 can conclude that high LC3 expression, lymph node metastasis, pancreatitis
17 and CA19-9 levels usually indicate the possibility of nerve invasion. Gender,
18 age, tumor site, tumor size, histological grade, clinical stage, vascular invasion,
19 and diabetes are not effective indicators of neural invasion and autophagy
20 and cannot be used as a determinant of resection of the peripancreatic nerve
21 during surgery.

22 The overall survival rates of the LC3 high-expression group and the
23 nerve-invasion group were significantly lower than those of the low-
24 expression group and the no-nerve-invasion group. Univariate analysis
25 showed that the level of CA19-9, PNI and autophagy were associated with
26 prognostic factors. Multivariate analysis showed that PNI and high LC3

1 expression were independent prognostic factors in pancreatic cancer patients.

2 Autophagy is very complex and often plays an important role in tumor
3 progression^[6, 29]. Interestingly, this study found that high autophagy level is
4 closely related to PNI, while both of which are independent risk factors for
5 pancreatic cancer with a poor prognosis. The autophagy associated with poor
6 survival in pancreatic cancer could be explain by the properties of autophagy
7 assisting cancer cells to evade stress-induced apoptosis in PNI environment
8 undoubtedly promote tumor cell survival^[30, 31]. Therefore, the high
9 autophagy of cancer cells may promote the malignant progression of
10 pancreatic cancer, resulting in PNI and the poor treatment outcome in
11 patients with the disease.

12 In summary, autophagy and PNI of pancreatic cancer cells are
13 independent risk factors for adverse prognosis. There is a significant
14 correlation between them, and there may be a pathway between them
15 through which they interact with each other to promote the malignant
16 progression of pancreatic cancer. How to control the role of autophagy in PNI
17 of pancreatic cancer and then improve cancer prognosis requires further
18 studies into the molecular mechanisms involved.

19

1 **FULL TEXT GUID**

2 *Research background*

3 Pancreatic cancer is a malignant tumor with a poor prognosis that has almost
4 equal mortality and morbidity in patients. At the time of diagnosis, most
5 pancreatic cancer patients have distant metastases due to early occult
6 symptoms, a lack of effective screening, and perineural growth characteristics.
7 The incidence of perineural invasion (PNI) in pancreatic cancer is 80-100%
8 and is an important factor leading to postoperative pancreatic cancer
9 recurrence. PNI evaluation of pancreatic cancer can predict disease recurrence
10 and prognosis after surgery. However, the pathogenesis of PNI has not yet
11 been defined .Autophagy, as a mechanism of anoikis avoidance in pancreatic
12 cancer, is closely related to the survival of pancreatic cancer cells.
13 Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a typical marker
14 of autophagy. LC3 labeling has been used to evaluate autophagy, and high
15 levels of LC3 expression have been found in pancreatic cancer cells. In
16 addition, another previous study showed that pancreatic cancer cells with
17 PNI have higher levels of autophagy. No study has examined the relationship
18 between autophagy and PNI in pancreatic cancer cells.

19 *Research motivation*

20 The relationship between autophagy and perineural invasion (PNI) was
21 explored for the first time in pancreatic cancer. Pancreatic cancer PNI is
22 related to LC3 expression-determined autophagy. PNI and LC3 expression
23 were independent prognostic factors in pancreatic cancer. There might be a
24 special association between autophagy and PNI, contributing to pancreatic
25 cancer progression. This study might provide a new insight for the
26 mechanism of PNI in pancreatic cancer.

27

28 *Research objectives*

1 This study focused on the relationship between pancreatic cancer cell
2 autophagy and PNI, clinicopathological features and prognosis . We found
3 that autophagy and PNI of pancreatic cancer cells are independent risk factors
4 for adverse prognosis. There is a significant correlation between them, and
5 there may be a pathway between them through which they interact with each
6 other to promote the malignant progression of pancreatic cancer. Controlling
7 the role of autophagy in PNI of pancreatic cancer may improve cancer
8 prognosis ,which requires further studies into the molecular mechanisms
9 involved.

11 *Research methods*

12 Clinical and pathological data were retrospectively collected from 109
13 patients with pancreatic ductal adenocarcinoma who underwent resection at
14 the First Affiliated Hospital of Zhengzhou University from January 2011 to
15 August 2016. Expression levels of the autophagy-related protein microtubule-
16 associated protein 1A/1B-light chain 3 (LC3) and perineural invasion marker
17 ubiquitin carboxy-terminal hydrolase (UCH) in pancreatic cancer tissues were
18 detected by immunohistochemistry. The correlations among LC3 expression,
19 perineural invasion, and clinical pathological features in pancreatic cancer
20 were analyzed. The patients were followed up for further survival analysis.

22 *Research results*

23 In this study, we found that LC3, lymph node metastasis, pancreatitis, and
24 CA199 level were factors that influenced neural invasion, whereas only neural
25 invasion itself was an independent factor of high LC3 expression. Perineural
26 invasion and LC3 expression were independent risk factors for poor
27 prognosis in pancreatic cancer. There is a significant correlation between them.

29 *Research conclusions*

1 This study focused on the relationship between pancreatic cancer cell
2 autophagy and PNI, clinicopathological features and prognosis . We found
3 that autophagy and PNI of pancreatic cancer cells are independent risk factors
4 for adverse prognosis. There is a significant correlation between them, and
5 there must be a pathway between them through which they interact with each
6 other to promote the malignant progression of pancreatic cancer. Controlling
7 the role of autophagy in PNI of pancreatic cancer may improve cancer
8 prognosis ,which requires further studies into the molecular mechanisms
9 involved.

10

1 **References**

- 2 1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin*
3 2016;**66**:7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]
- 4 2 **Zhang Y**, Dang C, Ma Q, Chen W, Nagata K. Predictors of systemic
5 chemotherapy contraindication in pancreatic cancer patients with distant
6 metastasis. *Journal of Modern Oncology* 2007;**54**:254-259 [PMID: 17419272]
- 7 3 **Hidalgo M**. Pancreatic cancer. *N Engl J Med* 2010;**362**:1605-1617 [PMID:
8 20427809 DOI: 10.1056/NEJMra0901557]
- 9 4 **Gillen S**, Schuster T, Meyer ZBC, Friess H, Kleeff J.
10 Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic
11 Review and Meta-analysis of Response and Resection Percentages. *PLoS Med*
12 2010;**7**:e1000267 [PMID:20422030DOI: 10.1371/journal.pmed.1000267]
- 13 5 **Zhou Y**, Zhou Q, Chen R. Pancreatic stellate cells promotes the perineural
14 invasion in pancreatic cancer. *Med Hypotheses* 2012;**78**:811-813 [PMID:
15 22513235 DOI: 10.1016/j.mehy.2012.03.017]
- 16 6 **Brech A**, Ahlquist T, Lothe RA, Stenmark H. Autophagy in tumour
17 suppression and promotion. *Mol Oncol* 2009;**3**:366-375 [PMID: 19559660 DOI:
18 10.1016/j.molonc.2009.05.007]
- 19 7 **Yang S**, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y,
20 Stommel JM, Dell'Antonio G. Pancreatic cancers require autophagy for tumor
21 growth. *Genes Dev* 2011;**25**:717-729 [PMID: 21406549 DOI:
22 10.1101/gad.2016111]
- 23 8 **Li J**, Ma Q, Liu H, Guo K, Li F, Li W, Han L, Wang F, Wu E. Relationship
24 between neural alteration and perineural invasion in pancreatic cancer
25 patients with hyperglycemia. *PLoS One* 2011; **6**: e17385 [PMID: 21386984 DOI:
26 10.1371/journal.pone.0017385]

1 9 **Zhu Z**, Friess H, Dimola FF, Zimmermann A, Graber HU, Korc M, Büchler
2 MW. Nerve growth factor expression correlates with perineural invasion and
3 pain in human pancreatic cancer. *J Clin Oncol* 1999;**17**:2419-2419 [PMID:
4 10561305 DOI: 10.1200/JCO.1999.17.8.2419]

5 10 **Moschidis A**, Papageorgiou A, Atmatzidis K, Tsalis K, Moschidis E,
6 Livanis J, Chrysogelou E, Mourelatos D, Tsavdaridis D, Harlaftis N.
7 Synergistic Antitumor Activity of Oxaliplatin in Combination with
8 Gemcitabine in Pancreatic Tumor-Bearing Mice. *Chemotherapy (Los Angel)*
9 2007;**53**:153-159 [PMID: 17347561 DOI: 10.1159/000100513]

10 11 **Takahashi H**, Akita H, Gotoh K, Kobayashi S, Marubashi S, Miyoshi N,
11 Sugimura K, Motoori M, Kishi K, Noura S. Preoperative gemcitabine-based
12 chemoradiation therapy for pancreatic ductal adenocarcinoma of the body
13 and tail: impact of splenic vessels involvement on operative outcome and
14 pattern of recurrence. *Surgery* 2015;**157**:484-495 [PMID: 25444512 DOI:
15 10.1016/j.surg.2014.09.022]

16 12 **Ryan DP**, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. *N Engl J Med*
17 2014;**371**:1039-1039 [PMID: 25207767 DOI: 10.1056/NEJMra1404198]

18 13 **Lee MG**, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU,
19 Woo SM. 5-Fluorouracil/Leucovorin Combined with Irinotecan and
20 Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with
21 Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based
22 Therapy. *Chemotherapy (Los Angel)* 2013;**59**:273-279 [PMID: 24457620 DOI:
23 10.1159/000356158]

24 14 **Agarwal JP**, Jain S, Gupta T, Tiwari M, Laskar SG, Dinshaw KA,
25 Chaturvedi P, D'Cruz AK, Shrivastava SK. Intraoral adenoid cystic carcinoma:
26 prognostic factors and outcome. *Oral Oncol* 2008;**44**:986-993 [PMID: 18329324
27 DOI: 10.1016/j.oraloncology.2008.01.004]

- 1 15 **Bapat AA**, Hostetter G, Von Hoff DD, Han H. Perineural invasion and
2 associated pain in pancreatic cancer. *Nat Rev Cancer* 2011;**11**:695-707 [PMID:
3 21941281 DOI: 10.1038/nrc3131]
- 4 16 **Akerberg D**, Ansari D, Andersson R. Re-evaluation of classical prognostic
5 factors in resectable ductal adenocarcinoma of the pancreas. *World J*
6 *Gastroenterol* 2016;**22**:6424-6433 [PMID: 27605878 DOI:
7 10.3748/wjg.v22.i28.6424]
- 8 17 **Liu B**, Lu KY. Neural invasion in pancreatic carcinoma. *Hepatobiliary*
9 *Pancreat Dis Int* 2002;**1**:469-469[PMID: 14607730]
- 10 18 **Cavel O**, Shomron O, Shabtay A, Vital J, Trejoleider L, Weizman N, Krelm
11 Y, Fong Y, Wong RJ, Amit M. Endoneurial macrophages induce perineural
12 invasion of pancreatic cancer cells by secretion of GDNF and activation of
13 RET tyrosine kinase receptor. *Cancer Res* 2012;**72**:5733-5743-[PMID: 22971345
14 DOI: 10.1158/0008-5472.CAN-12-0764]
- 15 19 **Li X**, Ma G, Ma Q, Li W, Liu J, Han L, Duan W, Xu Q, Liu H, Wang Z.
16 Neurotransmitter substance P mediates pancreatic cancer perineural invasion
17 via NK-1R in cancer cells. *Mol Cancer Res* 2013;**11**:294-294 [PMID: 23345604
18 DOI: 10.1158/1541-7786.MCR-12-0609]
- 19 20 **Abiatari I**, Deoliveira T, Kerkadze V, Schwager C, Esposito I, Giese NA,
20 Huber P, Bergman F, Abdollahi A, Friess H. Consensus transcriptome
21 signature of perineural invasion in pancreatic carcinoma. *Mol Cancer Ther*
22 2009;**8**:1494-1504 [PMID: 19509238 DOI: 10.1158/1535-7163.MCT-08-0755]
- 23 21 **Terman A**, Dalen H, Eaton JW, Neuzil J, Brunk UT. Mitochondrial
24 recycling and aging of cardiac myocytes: the role of autophagocytosis. *Exp*
25 *Gerontol* 2003;**38**:863-876 [PMID: 12915208 DOI: 10.1016/S0531-5565(03)00114-
26 1]

- 1 22 **Levine B**, Yuan J. Levine B, Yuan J. Autophagy in cell death: an innocent
2 convict? *J Clin Invest* 2005;**115**:2679-2688 [PMID: 16200202 DOI:
3 10.1172/JCI26390]
- 4 23 **Michaud M**, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P,
5 Shen S, Kepp O, Scoazec M, Mignot G. Autophagy-dependent anticancer
6 immune responses induced by chemotherapeutic agents in mice. *Science*
7 2011;**334**:1573-1577 [PMID: 22174255 DOI: 10.1126/science.1208347]
- 8 24 **Noman MZ**, Janji B, Kaminska B, Van MK, Pierson S, Przanowski P, Buart
9 S, Berchem G, Romero P, Mamichouaib F. Blocking hypoxia-induced
10 autophagy in tumors restores cytotoxic T-cell activity and promotes
11 regression. *Cancer Res* 2011;**71**:5976-5986 [PMID: 21810913 DOI:10.1158/0008-
12 5472.CAN-11-1094]
- 13 25 **Notte A**, Leclere L, Michiels C. Autophagy as a mediator of chemotherapy-
14 induced cell death in cancer. *Biochem Pharmacol* 2011;**82**:427-434 [PMID:
15 21704023 DOI: 10.1016/j.bcp.2011.06.015]
- 16 26 **Tanaka A**, Matsumura E, Yosikawa H, Uchida T, Machidera N, Kubo R,
17 Okuno K, Koh K, Watatani M, Yasutomi M. An evaluation of neural invasion
18 in esophageal cancer. *Surg Today* 1998;**28**:873-878 [PMID: 9744393 DOI:
19 10.1007/s005950050245]
- 20 27 **Ayala GE**, Dai H, Ittmann M, Li R, Powell M, Frolov A, Wheeler TM,
21 Thompson TC, Rowley D. Growth and survival mechanisms associated with
22 perineural invasion in prostate cancer. *Cancer Res* 2004;**64**:6082-6090 [PMID:
23 15342391 DOI: 10.1158/0008-5472.CAN-04-0838]
- 24 28 **Ozaki H**, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T,
25 Tsunoda T, Suzuki T, Monden M, Saitoh Y. The prognostic significance of
26 lymph node metastasis and intrapancreatic perineural invasion in pancreatic


1 cancer after curative resection. *Surg Today* 1999;**29**:16-22 [PMID: 9934826 DOI:
2 10.1007/BF02482964]

3 29 **Schmukler E**, Grinboim E, Schokoroy S, Amir A, Wolfson E, Kloog Y,
4 Pinkaskramarski R. Ras inhibition enhances autophagy, which partially
5 protects cells from death. *Oncotarget* 2013;**4**:142-152 [PMID:23370967 DOI:
6 10.18632/oncotarget.703]

7 30 **Mathew R**, Karantza-Wadsworth V, White E. Role of Autophagy in
8 Cancer. *Nat Rev Cancer* 2007;**7**:961-967 [PMID: 17972889 doi: 10.1038/nrc2254]

9 31 **Fujii S**, Mitsunaga S, Yamazaki M, Hasebe T, Ishii G, Kojima M, Kinoshita
10 T, Ueno T, Esumi H, Ochiai A. Autophagy is activated in pancreatic cancer
11 cells and correlates with poor patient outcome. *Cancer Sci* 2008;**99**:1813-1813
12 [PMID: 18616529 DOI: 10.1111/j.1349-7006.2008.00893.x]

13



1

2 **Fig. 1 Representative immunohistochemical results of LC3 and PNI. (A)**

3 Negative expression of LC3 in normal paraneoplastic pancreatic tissues (\times

4 200); (B) Negative expression of LC3 in pancreatic cancer tissues(\times 200); (C)

5 Weakly positive expression of LC3 in pancreatic cancer tissues(\times 200); (D)

6 Moderately positive expression of LC3 in pancreatic cancer tissues(\times 200); (E)

7 Strongly positive expression of LC3 in pancreatic cancer tissues(\times 200); (F-G)

8 Perineural invasion in pancreatic cancer tissues(\times 400, arrow represents

9 cancer cells infiltrating into nerve tissue); (H) Pancreatic cancer cells with high


10 LC3 expression enclosing and invading into nerve tissue (\times 200, arrow

11 represents cancer cells infiltrating into nerve tissue); (I) Pancreatic cancer cells

12 with high LC3 expression enclosing and invading into nerve tissue (\times 400,

13 arrow represents cancer cells infiltrating into nerve tissue).

14



1
 2 **Fig 2 Kaplan-Meier estimates of overall survival in patients underwent**
 3 **radical surgery . (A) The overall survival rate of the LC3 low-expression**
 4 **group was better than that of the high-expression group ($P<0.05$). (B) The**
 5 **overall survival rate of the patients without nerve invasion group was better**
 6 **than that of those with nerve infiltration ($P<0.05$).**
 7

- 1 **Table 1 Relationship between LC3 and perineural invasion expression in**
- 2 **pancreatic cancer.**

LC3	PNI		<i>P</i>	<i>r</i>
	Absent	Present		
low expression	18	22	0.018 ^a	0.227
high expression	16	53		

- 3 ^a*P* <0.05, PNI Absent *vs* Present.

1 **Table 2. Relationships of PNI and LC3 expression with clinicopathological**
 2 **features.**

Parameters	<i>n</i>	PNI		<i>P</i>	LC3		<i>P</i>
		Absent	Present		Low expression	High expression	
Age (years)							
≤58	54	19	35	0.373	23	31	0.206
>58	55	15	40		17	38	
Gender							
Male	61	15	46	0.093	26	35	0.148
Female	48	19	29		14	34	
Tumor location							
Head	66	17	49	0.129	28	38	0.124
Body/tail	43	17	26		12	31	
Tumor size							
≤2cm	18	6	12	0.83	8	10	0.455
>2cm	91	28	63		32	59	
Histologic grade							
Well or moderate	74	24	50	0.685	23	51	0.077
Poorly	35	10	25		17	18	
Vascular invasion							
Negative	83	26	57	0.957	31	52	0.801
Positive	26	8	18		9	17	
Lymph node metastasis							
Negative	36	17	19	0.011 ^a	18	18	0.043 ^a
Positive	73	17	56		22	51	
AJCC stage							
I+II	69	22	47	0.838	25	44	0.895
III+IV	40	12	28		15	25	

Pancreatitis							
Negative	30	15	15	0.009 ^a	12	18	0.659
Positive	79	19	60		28	51	
Diabetes							
Negative	89	27	62	0.684	33	56	0.862
Positive	20	7	13		7	13	
CA19-9 level							
≤37U/ml	37	19	19	0.001 ^a	13	24	0.808
>37 U/ml	72	15	57		27	45	

1 ^a*P* <0.05, LC3 Low expression *vs* High expression ; PNI Absent *vs* Present.

2

1 **Table 3 Logistic regression multivariate analysis of perineural invasion**
 2 **with clinicopathological features in pancreatic cancer.**

Parameters	Estimate, B	Standard error	Wald statistic	P-value	Odds ratio	95% CI
Lymph node metastasis (positive vs. negative)	1.068	0.499	4.581	0.032 ^a	2.911	1.094-7.743
CA199 (>37 vs. ≤37)	1.508	0.493	9.368	0.002 ^a	4.520	1.720-11.874
Pancreatitis (present vs. absent)	1.301	0.514	6.419	0.011 ^a	3.673	1.343-10.049
LC3 (high vs. low)	1.032	0.491	4.406	0.036 ^a	2.806	1.071-7.351
Constant	-7.209	1.799	16.058	0	0.001	

3 ^a*P* <0.05, CI: Confidence interval; LC3: Microtubule-associated protein 1A/1B-
 4 light chain 3 ; PNI : Perineural invasion .

5

6

1 **Table 4 Logistic regression multivariate analysis of LC3 expression with**
 2 **clinicopathological features in pancreatic cancer.**

Parameters	Estimate, B	Standard error	Wald statistic	P-value	Odds ratio	95% CI
PNI (present vs. absent)	0.997	0.427	5.451	0.02 ^a	2.71	1.174-6.259
Constant	-1.115	0.732	2.316	0.128	0.328	

3 ^a $P < 0.05$, PNI : Perineural invasion .

4

1 Table 5. Univariate analysis of survival in patients who underwent radical
 2 surgery.

Parameters	Hazard ratio	95% CI	P
PNI (present vs. absent)	3.701	1.539-8.903	0.003 ^a
LC3 (high vs. low)	3.196	1.433-7.126	0.005 ^a
Sex (male vs. female)	1.154	0.590-2.260	0.676
Age (>58 vs. ≤ 58)	1.176	0.621-2.225	0.619
Tumor location (body/tail vs head)	1.102	0.570-2.131	0.773
Histologic grade (poorly vs. well or moderate)	1.287	0.636-2.604	0.484
Tumor size (>2cm vs. ≤2cm)	0.94	0.444-1.991	0.871
Vascular invasion (positive vs. negative)	1.821	0.883-3.755	0.105
Lymph node metastasis (positive vs. negative)	0.871	0.449-1.688	0.682
AJCC stage (III+IV vs. I+II)	1.473	0.752-2.889	0.259
Diabetes (present vs. absent)	1.105	0.522-2.337	0.795
Pancreatitis (present vs. absent)	1.075	0.520-2.222	0.845
CA19-9 level (>37 vs. ≤37)	2.648	1.286-5.454	0.008 ^a

3 ^aP<0.05, LC3: Microtubule-associated protein 1A/1B-light chain 3 ; PNI :
 4 Perineural invasion .

5

6

1 **Table 6 Multivariable analysis of survival in patients who underwent**
2 **radical surgery.**

Parameters	Hazard ratio	95% CI	<i>P</i>
PNI (Present <i>vs</i> Absent)	2.962	1.212-7.238	0.017 ^a
LC3 (high <i>vs</i> Low)	2.491	1.107-5.608	0.027 ^a

3 ^a*P* <0.05. LC3: Microtubule-associated protein 1A/1B-light chain 3; PNI :
4 Perineural invasion .

5

6